课题基金 / 基金详情

CPCRA 046:EFFECTS OF ANTIRETROVIRAL MANAGEMENT BASED ON PLASMA GENOTY

CPCRA 046:EFFECTS OF ANTIRETROVIRAL MANAGEMENT BASED ON PLASMA GENOTY
CPRA 046:基于血浆基因的抗逆转录病毒治疗的效果
批准号:
6265769
负责人:
CHERYL L BESCH
金额:
$1.12万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-07-19 至 1999-11-30

项目摘要

项目成果

CHERYL L BESCH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of the GART Protocol is to determine the short-term effects of using plasma genotypic antiretroviral resistance testing (GART) in the management of antiretroviral therapy for antiretroviral-experienced patients failing while on one of the following four regimens: 1) ZDV + 3TC + IDV; 2) ZDV + 3TC +SQV; 3) ZDV + 3TC + RTV; or 4) d4T + 3 TC+ IDV. This is a multi-center randomized trial. An equal number of patients will be randomized in each stratum. Accrual is expected to take 24 weeks. Each patient will be followed for 12 weeks after randomization. Thus, the total study duration is expected to be 36 weeks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SAFETY AND EFFICACY OF ADEFOVIR DIPIVOXIL (BIS-POM-PMEA) IN SURVIVAL--HIV
  • 批准号:
    6122156
  • 项目类别:
  • 资助金额:
    $1.12万
  • 财政年份:
    1999
  • 负责人:
    CHERYL L BESCH
  • 依托单位:
CPCRA 059:IMPACT OF 2 DOSES OF SUBCUTANEOUS RECOMBINANT IL 2 ON VIRAL
  • 批准号:
    6265785
  • 项目类别:
  • 资助金额:
    $1.12万
  • 财政年份:
    1999
  • 负责人:
    CHERYL L BESCH
  • 依托单位:
CPCRA 045:EVALUATION OF HIV 1 GENOTYPIC RESISTANCE, VIRAL LOAD & CDS+
  • 批准号:
    6265778
  • 项目类别:
  • 资助金额:
    $1.12万
  • 财政年份:
    1999
  • 负责人:
    CHERYL L BESCH
  • 依托单位:
SAFETY & EFFICACY OF NELFINAVIR ADDED TO BACKGROUND ANTIRETROVIRAL NU
  • 批准号:
    6265767
  • 项目类别:
  • 资助金额:
    $1.12万
  • 财政年份:
    1999
  • 负责人:
    CHERYL L BESCH
  • 依托单位:
海外基金